Loading
Life sciences · Journal article
Experimental and Molecular Pathology · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Natural killer (NK) cell therapy has emerged as a promising approach for cancer treatment. However, its efficacy is often limited by metabolic dysfunction, poor persistence, and reduced activity within the tumor microenvironment. Here, we investigated whether mitochondrial transfer could improve the metabolic fitness and antitumor activity of peripheral blood-derived primary NK cells. Using a simple centrifugation-based approach, mitochondria isolated from NK cells or umbilical cord-derived mesenchymal stem cells (UC-MSCs) were transferred into primary NK cells. Mitochondrial transfer significantly enhanced oxidative phosphorylation, glycolysis, and ATP production, leading to improved cytokine secretion and cytotoxicity against both hematologic and solid tumor targets. In xenograft models, mitochondrial transfer significantly suppressed tumor growth, with UC-MSCs-derived mitochondria producing the greatest therapeutic benefit. Proteomic analysis further revealed enrichment of pathways associated with immune activation, cellular migration, and cytoskeletal remodeling. Collectively, these findings demonstrate that mitochondrial transfer enhances NK-cell metabolic fitness and antitumor activity, highlighting its potential as a practical non-genetic strategy for improving NK cell-based cancer immunotherapy.